AI Article Synopsis
- CD39 is an enzyme in a pathway that helps suppress the immune system and is linked to the growth and spread of solid tumors, particularly in skin-related cancers.
- Research found that CD39 is overexpressed in specific T-cell lymphomas, including Sezary syndrome and mycosis fungoides, in both blood and skin lymphocytes.
- The study suggests that blocking the CD39/CD73/adenosine pathway could be a promising approach for treating these types of cutaneous T-cell lymphomas.
Article Abstract
CD39, an ectoenzyme in the immunosuppressive CD39/CD73/adenosine pathway, known to promote solid tumour outgrowth and spreading, was investigated in both skin and blood compartments of cutaneous T cell lymphomas. CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988668 | PMC |
| http://dx.doi.org/10.1002/ski2.334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!